ATyr Pharma Analyst Ratings
BenzingaMar 15 12:47 ET
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
TipRanksMar 15 06:50 ET
Buy Rating Affirmed for ATyr Pharma as Lead Candidate Efzofitimod Advances in Clinical Trials With Solid Financial Footing
TipRanksMar 15 06:25 ET
ATyr Pharma Analyst Ratings
BenzingaMar 15 06:18 ET
ATyr Pharma Analyst Ratings
BenzingaFeb 21 11:14 ET
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), CVS Health (CVS) and Science 37 (SNCE)
TipRanksFeb 9 08:50 ET
ATyr Pharma (LIFE) Gets a Hold From Oppenheimer
TipRanksNov 22, 2023 07:55 ET
Promising Potential of ATyr Pharma's Efzofitimod in Treating Rheumatoid Arthritis and Associated Lung Disease Underpins Buy Rating
TipRanksNov 14, 2023 06:26 ET
RBC Capital Keeps Their Buy Rating on ATyr Pharma (LIFE)
TipRanksNov 10, 2023 20:48 ET
ATyr Pharma (LIFE) Receives a Buy From Piper Sandler
TipRanksNov 10, 2023 10:16 ET
Robust Financial Health and Promising Clinical Progress Prompt 'Buy' Rating for ATyr Pharma
TipRanksNov 10, 2023 06:46 ET
Promising Developments in ATyr Pharma's Efzofitimod Clinical Trials Lead to Buy Rating
TipRanksOct 31, 2023 10:06 ET
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE) and Pfizer (PFE)
TipRanksOct 31, 2023 10:01 ET
Piper Sandler Sticks to Its Buy Rating for ATyr Pharma (LIFE)
TipRanksOct 4, 2023 06:56 ET
Buy Rating for ATyr Pharma: Promising Developments in Efzofitimod Clinical Trials and Potential Expansion Opportunities
TipRanksSep 26, 2023 10:25 ET
ATyr Pharma (LIFE) Gets a Buy From Piper Sandler
TipRanksSep 26, 2023 06:35 ET
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Genfit SA (GNFT) and Boston Scientific (BSX)
TipRanksSep 21, 2023 06:32 ET
ATyr Pharma Analyst Ratings
BenzingaSep 21, 2023 06:22 ET
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Apellis Pharmaceuticals (APLS) and Harpoon Therapeutics (HARP)
TipRanksSep 14, 2023 06:21 ET
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
BenzingaSep 14, 2023 06:08 ET
No Data
No Data